| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.25 | 6e-08 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.22 | 2e-06 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0009 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.14 | 0.001 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |